[Receptor-mediated Parkinson drugs].
Böckler
Frank
F
Centre for Protein Engineering, Medical Research Council, Cambridge, United Kingdom. boeckler@pharmazie.uni-erlangen.de
D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001479:Basal Ganglia / Q000503:physiopathology; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D011954:Receptors, Dopamine / Q000187:drug effects; D011976:Receptors, Muscarinic / Q000187:drug effects; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects
D000978:Antiparkinson Agents; D018680:Cholinergic Antagonists; D011954:Receptors, Dopamine; D011976:Receptors, Muscarinic; D016194:Receptors, N-Methyl-D-Aspartate; D007980:Levodopa